Literature DB >> 26923850

Endocannabinoid concentrations in hair are associated with PTSD symptom severity.

Sarah Wilker1, Anett Pfeiffer2, Thomas Elbert2, Emilio Ovuga3, Alexander Karabatsiakis4, Aniko Krumbholz5, Detlef Thieme5, Gustav Schelling6, Iris-Tatjana Kolassa4.   

Abstract

The endocannabinoid system has been implicated in the regulation of the stress response, fear memory formation, and inflammatory processes. Posttraumatic stress disorder (PTSD) can result from exposure to extreme stress and is characterized by strong, associative memories for the traumatic events experienced. Furthermore, an elevated physical disease risk has been observed in PTSD, likely to be mediated by inflammatory processes. Therefore, altered endocannabinoid regulation can be expected in individuals with PTSD. However, attempts to assess PTSD-associated differences in the endocannabinoid system from human blood samples have provided inconsistent results, possibly due to fluctuating levels of endocannabinoids. In hair, these neuromodulators are accumulated over time and thus give access to a more stable and reliable assessment. We therefore investigated PTSD-associated differences in hair concentrations of endocannabinoids (N-acyl-ethanolamides palmitoylethanolamide [PEA], oleoylethanolamide [OEA] and stearoylethanolamide [SEA]) in 38 rebel war survivors from Northern Uganda suffering from PTSD and N=38 healthy rebel war survivors without current and lifetime PTSD. PTSD diagnosis and symptom severity were assessed in structured clinical interviews employing the Posttraumatic Diagnostic Scale (PDS). A significant group difference was observed for OEA, with PTSD patients showing reduced hair concentrations. Regression analyses further revealed strong negative relationships between all investigated N-acyl-ethanolamides and symptom severity of PTSD. The observed reductions in endocannabinoids might account for the increased inflammatory state as well as for the failure to extinguish fear memories observed in PTSD. Our findings add to the accumulating evidence suggesting the endocannabinoid system as a target for pharmacological enhancement of exposure-based psychotherapy for PTSD.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Endocannabinoids; Hair; Mass spectrometry; Oleoylethanolamine; Palmitoylethanolamide; Posttraumatic stress disorder; Stearoylethanolamine

Mesh:

Substances:

Year:  2016        PMID: 26923850     DOI: 10.1016/j.psyneuen.2016.02.010

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  24 in total

Review 1.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

Review 2.  A review of the effects of acute and chronic cannabinoid exposure on the stress response.

Authors:  Nicholas C Glodosky; Carrie Cuttler; Ryan J McLaughlin
Journal:  Front Neuroendocrinol       Date:  2021-08-28       Impact factor: 8.333

3.  Hair-based biomarkers in women with major depressive disorder: Glucocorticoids, endocannabinoids, N-acylethanolamines, and testosterone.

Authors:  Alexander Behnke; Anja M Gumpp; Aniko Krumbholz; Alexandra M Bach; Gustav Schelling; Iris-Tatjana Kolassa; Roberto Rojas
Journal:  Compr Psychoneuroendocrinol       Date:  2021-06-21

4.  Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety.

Authors:  Andalib Danandeh; Valentina Vozella; James Lim; Fariba Oveisi; Gina L Ramirez; David Mears; Gary Wynn; Daniele Piomelli
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

Review 5.  Context Processing and the Neurobiology of Post-Traumatic Stress Disorder.

Authors:  Israel Liberzon; James L Abelson
Journal:  Neuron       Date:  2016-10-05       Impact factor: 17.173

Review 6.  Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.

Authors:  Matthew E Sloan; Caroline W Grant; Joshua L Gowin; Vijay A Ramchandani; Bernard Le Foll
Journal:  Acta Pharmacol Sin       Date:  2018-08-30       Impact factor: 6.150

7.  Endocannabinoids and Precision Medicine for Mood Disorders and Suicide.

Authors:  Graziano Pinna
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

8.  Pharmacological Blockade of PPARα Exacerbates Inflammatory Pain-Related Impairment of Spatial Memory in Rats.

Authors:  Jessica C Gaspar; Catherine Healy; Mehnaz I Ferdousi; Michelle Roche; David P Finn
Journal:  Biomedicines       Date:  2021-05-27

Review 9.  Endocannabinoid-mediated neuromodulation in the main olfactory bulb at the interface of environmental stimuli and central neural processing.

Authors:  Thomas Heinbockel; Naina Bhatia-Dey; Vonnie D C Shields
Journal:  Eur J Neurosci       Date:  2021-04-02       Impact factor: 3.698

10.  Serum profile changes in postpartum women with a history of childhood maltreatment: a combined metabolite and lipid fingerprinting study.

Authors:  Alexandra M Koenig; Alexander Karabatsiakis; Thomas Stoll; Sarah Wilker; Thomas Hennessy; Michelle M Hill; Iris-Tatjana Kolassa
Journal:  Sci Rep       Date:  2018-02-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.